{"url_path":"/sec/immx/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-024707-index.html","accession_number":"0001493152-26-024707","cik":"0001873835","ticker":"IMMX","issuer_name":"Immix Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1873835/0001493152-26-024707-index.html","primary_entity_key":"0001873835","primary_entity_name":"Immix Biopharma, Inc."},"word_count":799,"has_tables":true,"body_markdown":"**Item\n8.01 Other Events.**\n\n** **\n\nOn\nMay 21, 2026, the Company announced an update from the Phase 2 NEXICART-2 NXC-201\nclinical trial, including that all four MRD-negative relapsed/refractory AL Amyloidosis\npatients announced by the Company at the ASH 2025 have converted to CR. Of the first 20 patients in NEXICART-2, all MRD-negative\npatients have converted to CR, increasing the CR rate to 95% (19/20). No relapses have been observed to date for patients who have\nreached CR, and all CRs were reached within one year of follow-up post-dosing. Additionally, MRD-negativity 10-5 was\nachieved within 30 days for all MRD-negative patients. As of May 14, 2025, 17 of 20 patients in\nNEXICART-2 showed rapid normalization of diseased light chains in patients with a median time to initial response of 7 days. Safety\ndata through May 14, 2026 has been generally consistent with previous safety data observed and reported in NEXICART-2 trial. The\nnext NEXICART-2 update is expected in late September 2026. NEXICART-2\nis a fully enrolled 45-patient multi-site U.S. Phase 2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory\nAL Amyloidosis, with a potentially registrational design. A multi-center, randomized, Phase 3\ntrial of NXC-201 in newly diagnosed AL Amyloidosis patients is planned to be initiated in the first half of 2027.\n\n \n\n**Risk\nFactors**\n\n \n\nThe\nrisk factor listed below should be read in conjunction with the risk factors disclosed in the Company’s Annual Report on Form 10-K\nfor the year ended December 31, 2025.\n\n \n\n**Interim\ndata from clinical trials are subject to various risks, including that final results may be materially different than those reflected\nin any interim data and that third parties, including regulatory agencies may disagree with the analysis used to interpret the interim\ndata.**\n\n \n\nInterim\ndata from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as more data on existing\npatients become available. When a clinical trial is ongoing, the final results from the trial may be materially different from those\nreflected in any interim data the Company reports.\n\n \n\nFurther,\nothers, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses\nor may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability\nor commercialization of the particular product candidate or product and the value of the Company in general. In addition, the information\nthe Company chooses to publicly disclose regarding a particular study or clinical trial is typically a summary of extensive information,\nand you or others may not agree with what the Company determines is the material or otherwise appropriate information to include in its\ndisclosure. Any information the Company determines not to disclose may ultimately be deemed significant with respect to future decisions,\nconclusions, views, activities or otherwise regarding a particular product, product candidate or its business. If the interim data that\nthe Company reports differs from actual results, or if others, including regulatory authorities, disagree with the conclusions reached,\nthe Company’s ability to obtain approval for, and commercialize, its product candidates, including NXC-201, may be harmed.\n\n \n\n**Cautionary\nNote Regarding Forward-Looking Statements**\n\n \n\nThis\nCurrent Report contains “forward-looking” statements within the meaning of the Securities Act, the Securities Exchange\nAct of 1934, as amended, and of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995,\nincluding, but not limited to statements regarding the expected timing of the next NEXICART-2 update and the Company’s plans\nto initiate a multi-center, randomized, Phase 3 trial of NXC-201 in newly diagnosed AL Amyloidosis\npatients, including the timing thereof. All statements other than statements of historical fact are statements that could be deemed\nforward-looking statements. The words “believes,” “anticipates,” “estimates,”\n“plans,” “expects,” “intends,” “may,” “could,” “should,”\n“potential,” “likely,” “projects,” “continue,” “will,”\n“schedule,” and “would” and similar expressions are intended to identify forward-looking statements,\nalthough not all forward-looking statements contain these identifying words. These forward-looking statements are predictions based\non the Company’s current expectations and projections about future events and various assumptions, including without\nlimitation regarding the timing and results of the Company’s clinical trials, and the regulatory landscape. Forward-looking\nstatements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ\nsignificantly from those expressed in any forward-looking statement, including risks and uncertainties described herein, under the\nheading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, its\nQuarterly Reports on Form 10-Q and other documents that the Company files from time to time with the SEC. The forward-looking\nstatements in this Current Report speak only as of the date hereof, the Company undertakes no obligation to revise or update any\nforward-looking statements to reflect events or circumstances after the date hereof, except as may be required by law."}